Clinical Trials Logo

Tumors Metastatic to Brain clinical trials

View clinical trials related to Tumors Metastatic to Brain.

Filter by:

NCT ID: NCT02312622 Completed - Clinical trials for Tumors Metastatic to Brain

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02277561 Withdrawn - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery

Start date: April 2013
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well voxel based diffusion tensor imaging in predicting response in patients with brain metastases undergoing whole-brain radiation therapy or stereotactic radiosurgery. Voxel based diffusion tensor imaging (VB-DTI) may allow doctors to measure response to whole brain radiation therapy or stereotactic radiosurgery earlier than is possible with a standard magnetic resonance imaging. The earlier ability to measure response may allow for consideration of alternative therapies at an earlier stage.

NCT ID: NCT02269111 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

Start date: April 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to routine care brain imaging of the brain, this study will include advanced multiparametric MRI sequences to measure vascular, cellular, and molecular properties of the tumor. Performing extra scans during MRI provides more information about the metastases and may better predict treatment response.

NCT ID: NCT02145910 Withdrawn - Stage IV Melanoma Clinical Trials

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Start date: n/a
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose of vemurafenib when combined with whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) in patients with v-raf murine sarcoma viral oncogene homolog B (BRAF) mutation-positive melanoma and brain metastases. Radiation therapy is an effective treatment for patients with brain metastases. Patients with multiple metastases are typically treated with WBRT. For patients with a few metastases, SRS alone can be used. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Combining radiation treatment with vemurafenib for melanoma patients with brain metastases may result in improved local control and prolonged survival.

NCT ID: NCT02107755 Completed - Liver Metastases Clinical Trials

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Start date: September 5, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic). Stereotactic radiation therapy is a type of external beam radiation therapy that uses special equipment to position the patient and precisely give a either a single large dose of radiation therapy to a tumor or several large doses of radiation therapy to a tumor using precision and accuracy that is guided by onboard daily imaging prior to radiation therapy. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some monoclonal antibodies find tumor cells and help kill them or carry tumor-killing substances to them. Giving stereotactic radiosurgery together with ipilimumab may kill more tumor cells by causing addition melanoma antigens to be presented to the immune system.

NCT ID: NCT01891318 Recruiting - Clinical trials for Tumors Metastatic to Brain

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

Start date: July 3, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase I/II trial studies the ability to stop brain metastases from coming back after treatment with radiosurgery followed by surgical resection. It will also evaluate the side effects of these combined treatments and help determine the best radiosurgery dose. Radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.

NCT ID: NCT01843413 Suspended - Clinical trials for Tumors Metastatic to Brain

Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases

Start date: July 2, 2013
Phase: N/A
Study type: Interventional

This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

NCT ID: NCT01706432 Active, not recruiting - Liver Metastases Clinical Trials

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

Start date: June 15, 2009
Phase:
Study type: Observational

This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.

NCT ID: NCT01703507 Completed - Stage IV Melanoma Clinical Trials

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Start date: November 9, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ipilimumab when given together with whole brain radiation therapy or stereotactic radiosurgery in treating patients with melanoma with brain metastases. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of the tumor to grow and spread. Others find Tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy, such uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells. Giving ipilimumab together with whole-brain radiation therapy or stereotactic radiosurgery may kill more tumor cells.

NCT ID: NCT01276210 Completed - Clinical trials for Tumors Metastatic to Brain

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Start date: February 2011
Phase: Phase 1
Study type: Interventional

RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Stereotactic radiosurgery (SRS) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving sorafenib tosylate together with SRS may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and the best dose of sorafenib tosylate when given together with SRS in treating patients with brain metastases